Who is sponsoring NCT03023475?

NCT03023475 is sponsored by Kerckhoff Klinik.

What drugs are being tested in NCT03023475?

Interventions in NCT03023475: LigaSure endoscopic vessel harvesting, TLS2 endoscopic vessel harvesting.

What condition does NCT03023475 study?

NCT03023475 studies CABG Graft Integrity.

Is NCT03023475 still recruiting?

NCT03023475 is currently completed. Last updated 25 February 2020.

Last reviewed 2020-02-25 · How we verify

NCT03023475

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Two Different Endoscopic Radial Artery Harvesting Devices

Completed NA Last updated 25 February 2020

What this trial tests

NA trial testing LigaSure endoscopic vessel harvesting in CABG Graft Integrity in 100 participants. Completed in 28 February 2018.

Timeline

1 February 2017

Primary endpoint
30 September 2017

28 February 2018

Quick facts

Lead sponsor	Kerckhoff Klinik
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 February 2017
Primary completion	30 September 2017
Estimated completion	28 February 2018
Sites	1 location across Germany

Drugs / interventions tested

LigaSure endoscopic vessel harvesting
TLS2 endoscopic vessel harvesting

Conditions studied

CABG Graft Integrity — all drugs for CABG Graft Integrity →

Sponsor

Kerckhoff Klinik

Who can join

18 and older, any sex, with CABG Graft Integrity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Endoscopic radial artery harvesting in coronary bypass surgery is routinely performed by the investigators. In this study, the investigators want to compare the MiFusion TLS2 (Endotrust GmbH, Germany) device to the LigaSure Maryland Jaw (Medtronic, USA). The vessel harvesting is performed in the standard fashion according to the institutional routine. The patients are randomized preoperatively to one of the devices. The proximal end of the radial artery will be preserved and deep-frozen for histological assessment. Endothelial integrity will be investigated using Hematoxylin-Eosin, CD31 and endothelial nitrogen monoxide synthase.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Kerckhoff Klinik trials

Trials by the same sponsor.

NCT07299227 — Impact of BPA in CTEPH on Cardiac and Pulmonary Physiology Assessed by CMR-derived 4D Flow Haemodynamics · recruiting
NCT07018778 — CMR-derived Quantitative Perfusion for Prediction of FFR · not yet recruiting
NCT04111744 — Preoperative Excercise Training for Patients Undergoing Coronary Artery Bypass Graft Surgery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03023475 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kerckhoff Klinik
Last refreshed: 25 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03023475.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing